Untitled

[janessaclaudia]

Cost of Sunitinib (Sutent) per Month - GenuineDrugs123

Sunitinib (Sutent) Health product prices can fluctuate based on factors like dosage, location, and insurance coverage. It's crucial to consult with healthcare providers and insurers for precise cost details. The availability of generic versions or patient assistance programs may also impact expenses. Keep in mind that health product prices can change, so it's recommended to check current figures with updated sources, such as GenuineDrugs123.com, for the guaranteed lowest price of Sunitinib (Sutent) 12.5 mg at $5.5 per capsules online.

Find other Anti-Cancer Drugs Generic Dasatinib Brand Sprycel Online at - https://www.genuinedrugs123.com/14-Anti-Cancer-Drugs-Generic-Dasatinib-Brand-Sprycel.aspx

[janessaclaudia]

Activity and safety of sunitinib in poor risk metastatic renal cell carcinoma patients

Over the past few years, several new agents have been granted approval for the first-line treatment of metastatic renal cell carcinoma (mRCC). These agents include inhibitors of the vascular endothelial growth factor (VEGF) pathway (sunitinib, pazopanib, bevacizumab) and inhibitors of the mammalian target of rapamycin (mTOR) pathway (temsirolimus).

[janessaclaudia]

Sunitinib (Sutent) for renal tumours

Sunitinib can cause different side effects in different people. Some are more likely to occur than others. Everyone is different and not everyone gets all the side effects. Most side effects are usually temporary, but in some rare cases they can be life-threatening. It is important to tell your hospital doctor or nurse about any side effects so they can be monitored and, where possible, treated.

[janessaclaudia]

New insights into molecular mechanisms of sunitinib-associated side effects

Tyrosine kinase inhibitors (TKI) are a novel type of drug, designed to target signaling pathways deregulated in cancer by blocking the ATP-binding pocket of specific receptor tyrosine kinases (RTK). TKIs compete with ATP for binding to the intracellular domain of wild-type and/or mutant forms of RTKs and, consequently, inhibit signal transduction.

Although TKIs are designed to target specific RTKs, it is increasingly apparent that many TKIs may display unexpected effects on other kinases and may trigger the appearance of undesirable side effects. The observed incidence of side effects associated with TKIs varies between clinical studies, depending on treatment schedule, dosage, patient characteristics, predisposing factors, secondary diseases, and concurrent administration of other drugs. Moreover, these agents, which do not specifically target tumor cells, are able to act on normal cells, eliciting diverse side effects.

[janessaclaudia]

About Sunitinib (Sutent)

A kinase is an enzyme that promotes cell growth. There are many types of kinases, which control different phases of cell growth. By blocking a particular enzyme from working, this medication can slow the growth of cancer cells. Sunitinib is a type of targeted therapy called a multikinase inhibitor. and it works by blocking two processes that allow cancer cells to grow. First, it interferes with a protein that promotes cell division. It also works by blocking the VEGF receptor, which is responsible for angiogenesis, or the development of a blood supply to the tumor. This removes the tumor's source of nutrients.

[janessaclaudia]

TTP-HUS Associated with Sunitinib

Thrombotic thrombocytopenic purpura-hemolytic uremic synrome (TTP-HUS) is a rare condition that is severe and may be fatal. TTP-HUS is a spectrum of syndromes with common features of thrombocytopenia and microangiopathic hemolytic anemia (MAHA). Although the majority of cases have no evident triggering event, several etiologic causes have been identified. Adverse reactions to drugs are increasingly reported as probable causes of TTP-HUS. Recognition of a drugassociated etiology in patients with TTP-HUS is critical to avoid re-exposure and recurrent events.